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Dear Editor,
Prostate cancer (CaP) is a common cause of cancer death
in males in Europe and North America.
1,2 Despite screening
for prostate-speciﬁc antigen has led to an early diagnosis,
it has not resulted in the desired decrease of mortality mainly
due to cancer recurrence and metastatic desease. Although
radical prostatectomy, radiation and androgen ablation
are effective therapies for androgen-dependent CaP, meta-
static castration-resistant (CR) CaP is a major complication
associated with high mortality rates. Although most patients
initially respond to androgen ablation therapy, many become
resistant within 18 months.
1,2 It is therefore of uttermost
importance to determine the molecular mechanism leading to
the emergence of CR-CaP and to identify predictive markers
of progression. Recently, we have shown that castration
results in massive inﬂammatory inﬁltration in the tumor
remnant, and that inﬁltrating B cells promote tumor growth
by lymphotoxin production that results in IKKa nuclear
translocation and activation that in turn promotes tumor
growth with a NF-kB-independent mechanism.
3
We have previously shown that BAG3, a member of the
BAG family of heat-shock proteins co-chaperons, is over-
expressed in numerous cancers and promotes tumor cell
survival
4,5 by preventing HSP-70-dependent IKKg degrada-
Figure 1 (a) myc-CaP cells derived from the FVB background were provided by C Sawyers (University of California, Los Angeles and Memorial Sloan Kettering Cancer
Center).
3Virus-containingsupernatantswereaddedtothecellsfor2dayswithpolybrene,andtransducedcellswereselectedin5mg/mlpuromycin(Invitrogen,Carlsbad,CA,
USA). MaleFVB mice wereinjected with myc-CaP cells, previouslyinfectedwith lentivirusesexpressingcontrol(Scrambled) or BAG3-speciﬁc siRNAs. When tumors reached
900mm
3,mice(n¼10pergroup)werecastrated.Tumorsizewasmeasuredevery2–3days.Resultsareexpressedasmeans±S.D.DatawereanalyzedbyStudent’st-test
usingGraphPadPrismstatisticalprogram(*Po0.001).(b)ParafﬁnsectionsoftumorstransducedwithBAG3siRNA(rightpanel)orcontrolvector(leftpanel)asdescribedina
werestainedusingaspeciﬁcantibodyrecognizingIKKa(Imgenex,SanDiego,CA,USA)andcounterstainedwithhematoxylinaspreviouslydescribed
3(originalmagniﬁcation
 200). (c) myc-CaPcells were infected with a lentiviruscarrying a control (Scrambled; left panel) or a BAG3-speciﬁc siRNA (right panel) then treatedwith LTa2b1, TGFb or
RANKL,allat10ng/ml(Sigma,Aldrich,St.Louis,MO,USA)for1h.Cellswereharvestedandsubjectedtonuclei/cytosolfractionation.Lysateswereanalyzedbyimmunoblot,
using the same antibody as in b (C, cytosol; N, nucleus).
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6 We and others have
shown that BAG3 is expressed in CaPs;
7,8 we therefore
investigated the possibility that BAG3 has a role also in
CR-CaP growth. To this end we examined if BAG3 deletion
was able to delay the emergence of CR-CaP, using the
myc-CaP allograft model previously described.
3 BAG3 short
hairpin RNA (shRNA) was cloned into pLSLPw, and lenti-
virus stocks prepared as previously described.
9 myc-CaP
cells were transduced with the virus and selected in
puromycin. FVB male mice were SC injected with myc-CaP
cells, previously infected with lentiviruses expressing
control (Scrambled) or BAG3-speciﬁc siRNAs. When tumors
reached 900mm
3, mice were castrated and tumor size
measured every 2–3 days. As shown in Figure 1a, down-
regulation of BAG3 signiﬁcantly delays the emergence of
CR-CaP tumors following androgen ablation. The delay in
tumor growth observed in BAG3-silenced tumors resembles
the delay observed when IKKa is deleted, suggesting that
BAG3 modulation was affecting IKKa levels or localization.
Interestingly, tumor staining for IKKa shows that reduction
of BAG3 results in a strong inhibition of IKKa nuclear trans-
location (Figure 1b). We therefore investigated whether
BAG3wasrequiredforIKKanucleartranslocationinresponse
to inﬂammatory cytokines. To this purpose, myc-CaP cells
were infected with lentivirus carrying a BAG3-speciﬁc
shRNA or a scrambled control sequence and treated for
1h with LT-a, or TGF-b or RANKL. As shown in Figure 1c,
treatment with any of this cytokines results in IKKa nuclear
translocation that is strongly reduced in cells transduced
with BAG3 shRNA. These results demonstrate that BAG3 is
required for IKKa nuclear translocation in response to
inﬂammatory cytokines.
Altogether, our data demonstrate that BAG3 has an
essential role in promoting the emergence of CR-CaP
by modulating IKKa nuclear translocation in response to
cytokines produced by inﬁltrating inﬂammatory cells, most
likely B-cell-derived lymphotoxin in accordance with our
previously published data.
3 These observation suggest that
BAG3 is a potential marker of CaP aggressiveness and of
response to androgen ablation therapy, and is also a potential
target for future therapies. More work needs to be performed
to clearly correlate BAG3 expression to clinical outcome
as well as to clarify the molecular mechanism through
which BAG3 inﬂuences IKKa nuclear translocation. We can
imagine at least two scenarios, in the ﬁrst one BAG3 is
required to release IKKa from another binding protein that
prevents its nuclear translocation, in the second one BAG3
itself would shuttle IKKa to the nucleus, in support of this
second mechanism are some preliminary data from our
laboratory showing BAG3 nuclear localization in some CaP
cell lines.
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